Iconeus was founded in 2016 in Paris by a team of experienced professionals from INSERM, the French National Institute for Health & Medical Research. Pioneering inventors of functional ultrasound imaging with more than 60 years of combined experience in wave physics, biomedical ultrasound and neuroscience, teamed up with the health industry specialist Ludovic Lecointre, now CEO of our company. The founders, now the Scientific Advisors of Iconeus, typically meet once a week with the CEO and the CTO, to ensure the seamless translation of cutting-edge research advances and of scientific network information into Iconeus products and know-how.
Mickael Tanter, PhDINSERM Research ProfessorMickael Tanter is an INSERM Research Professor and a distinguished professor at ESPCI Paris, heading its “Physics for Medicine” laboratory. He is globally renowned expert in biomedical ultrasound and wave physics, and has authored more than 300 peer-reviewed papers and book chapters. He is an elected member of the European Academy of Science and the recipient of 45 international patents and has co-invented several major innovations in biomedical ultrasound: transient elastography, ultrafast ultrasound and shear wave elastography, functional ultrasound imaging of brain activity and super-resolution ultrasound. He has received, among other distinctions, the Honored Lecturer of the Radiological Society of North America in 2012, the Grand Prize of the French Foundation of Medical Research in 2016 and the Carl Hellmuth Hertz Prize of the IEEE Ultrasonics Society in 2017. Co-founder of several MedTech companies in biomedical ultrasound (Supersonic Imagine, CardiaWave), he pioneered neurofunctional ultrasound together with his team, a technology that today is marketed commercially by Iconeus.
Zsolt Lenkei, MD, PhDINSERM Research DirectorZsolt Lenkei graduated in 1992 from Semmelweis University's Faculty of Medicine in Budapest, Hungary. He obtained a PhD in Neurosciences from the University Pierre and Marie Curie in Paris in 1998, while working at the Chaire de Médecine Experimentale of the College de France, Paris. After a post-doc at the Montreal Neurological Institute of McGill University, Canada, he obtained a tenured research position at INSERM. He established an independent research team under his leadership at ESPCI Paris. He was recently recruited as senior team leader to the new Institute of Psychiatry and Neurosciences of Paris at INSERM. He is an internationally recognized specialist in the neuronal cell biology of cannabinoid receptors, as shown by the many invitations he receives internationally to lecture on the topic and by his recent election as co-chair of the Gordon Conference on Cannabinoids 2019. He has a proven track record of success in contributing to interdisciplinary projects that include renowned physicists and chemists, collaborations that have yielded many important publications and patents.
Ludovic LecointreChief Executive OfficerLudovic Lecointre holds a Doctor of Pharmacy degree, and has a primary background in chemistry. After holding executive R&D positions at pharmaceutical companies such as Bristol-Myers Squibb, Parke-Davis and Pfizer, he ran his own company (13 employees, €3.5 million in annual sales) in the field of health for 12 years. Alongside this, he was appointed to the French national health agency as an expert on chemistry, manufacturing and controls (CMC) for drug registration filings.
Mathieu Pernot, PhDINSERM Research DirectorMathieu Pernot graduated in 2001 from ESPCI-Paris and obtained a PhD in Physics from Paris Diderot University ("Paris 7") in 2004. After a post-doctoral fellowship at Columbia University, he joined SuperSonic Imagine, in 2006, a startup company that developed the first clinical ultrafast ultrasound scanner. Currently deputy director of the INSERM “Physics for Medicine” unit at ESPCI Paris, he received in 2012 a prestigious ERC Grant. He also received the IEEE UFFC Outstanding Paper Award in 2010 and 2016 and the Robert’s prize in 2015. His research focuses on the development of wave physics for biomedical imaging and therapy including ultrafast ultrasound imaging, cardiovascular applications and non-invasive therapeutic ultrasound. He has been granted 26 patent families in the field of ultrasonic therapy and imaging. He also co-founded Cardiawave in 2014, a startup company developing the first clinical ultrasound device for non-invasive therapy of aortic calcified valves.
Thomas Deffieux, PhDINSERM Research Associate ProfessorThomas Deffieux obtained his PhD in Physics from Paris Diderot University ("Paris 7") in 2008 working on ultrafast ultrasound imaging and shear-wave elastography. After a post-doctoral fellowship at Columbia University dedicated to research on the blood-brain barrier using non-invasive focused ultrasound and microbubbles, he joined the Langevin Institute in 2011. His current research focuses on the development of wave physics for biomedical imaging and therapy including ultrafast ultrasound imaging, functional ultrasound imaging and non invasive ultrasound neuromodulation using innovative approaches.
Bruno Osmanski, PhDChief Technical OfficerBruno Osmanski graduated in 2010 from ESPCI Paris, a leading French engineering school. That same year, he also obtained a master’s in fundamental acoustics from Paris Diderot University. He obtained his PhD in 2014 at the Langevin Institute, in ultrafast imaging for blood flow applications, including functional ultrasound imaging of the brain. He joined the Neurophysiology & New Microscopies Laboratory (Prof. Serge Charpak, INSERM) as a postdoctoral scientist to study the mechanisms of neurovascular coupling using functional ultrasound, fMRI and two-photon imaging.